171![NDA[removed]S-021 Page 3 AVAPROâ (irbesartan) Tablets USE IN PREGNANCY NDA[removed]S-021 Page 3 AVAPROâ (irbesartan) Tablets USE IN PREGNANCY](https://www.pdfsearch.io/img/ede90f0607908a5f88af5811a6aba934.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2006-03-14 13:56:22
|
---|
172![Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Memorandum Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Memorandum](https://www.pdfsearch.io/img/8842ba1c53fb606ad228b6fa3e2378d4.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2006-03-14 13:56:21
|
---|
173![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COREG safely and effectively. See full prescribing information for COREG. • HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COREG safely and effectively. See full prescribing information for COREG. •](https://www.pdfsearch.io/img/a228f324da47409e8750db61d049c0c6.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-01-31 14:17:54
|
---|
174![• History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to carvedilol or any of the components of COREG CR. (4) ----------------------- WARNINGS AND PRECAUTIO • History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to carvedilol or any of the components of COREG CR. (4) ----------------------- WARNINGS AND PRECAUTIO](https://www.pdfsearch.io/img/536db2b1741eb9ce44e23676e5510419.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-01-31 14:17:54
|
---|
175![• Renal failure: Monitor renal function after initiation and HIGHLIGHTS OF PRESCRIBING INFORMATION periodically in patients with moderate to severe renal impairment (CrCL < 60 mL/min). If acute renal failure develops, • Renal failure: Monitor renal function after initiation and HIGHLIGHTS OF PRESCRIBING INFORMATION periodically in patients with moderate to severe renal impairment (CrCL < 60 mL/min). If acute renal failure develops,](https://www.pdfsearch.io/img/8b5d7056a9c5bc04607fe20d8d985ab7.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2013-12-23 15:37:49
|
---|
176![• HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for Valturna. • HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for Valturna.](https://www.pdfsearch.io/img/201c9bc40ef38efe573969babe71a99a.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-05-05 14:18:21
|
---|
177![HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for](https://www.pdfsearch.io/img/580e62ae07443444ca69420cee118eba.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-02-11 15:07:03
|
---|
178![-----------------------CONTRAINDICATIONS------------------------ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr -----------------------CONTRAINDICATIONS------------------------ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr](https://www.pdfsearch.io/img/30899c2601d0342663e3d1179106c3ea.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2012-01-23 13:06:56
|
---|
179![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEKAMLO safely and effectively. See full prescribing information for TEKAMLO. Tekamlo (aliskiren and amlodipine) tab HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEKAMLO safely and effectively. See full prescribing information for TEKAMLO. Tekamlo (aliskiren and amlodipine) tab](https://www.pdfsearch.io/img/048b01f207b36c1894b22b2a850f082b.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-04-01 15:41:03
|
---|
180![-----------------WARNINGS AND PRECAUTIONS----------------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescribing -----------------WARNINGS AND PRECAUTIONS----------------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescribing](https://www.pdfsearch.io/img/c585c71d6c425ee83e82db57ea8856b2.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-06-07 09:40:04
|
---|